Meta Platforms, Inc. is downgraded to a Hold rating given fair valuation and capped upside. Learn more about META stock here.
MedPage Today on MSN
Meta-Analyses Argue for Broader Use of SGLT2 Inhibitors in Chronic Kidney Disease
The first meta-analysis analyzed 70,361 participants from 10 randomized trials, and found those allocated to receive an SGLT2 ...
Abstract: This paper presents a new isolated topology for high-step-down applications. The proposed converter derives from DSD (double-step-down) converter employing one flying capacitor as energy bus ...
The proof-of-concept could pave the way for a new class of AI debuggers, making language models more reliable for business-critical applications.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback